Document is current
Any future updates will be listed below
-
Authors
Bogdanovich, Sasha
Kim, Younghee
Mizutani, Takeshi
Yasuma, Reo
Tudisco, Laura
Cicatiello, Valeria
Bastos-Carvalho, Ana
Kerur, Nagaraj
Hirano, Yoshio
Baffi, Judit Z
Tarallo, Valeria
Li, Shengjian
Yasuma, Tetsuhiro
Arpitha, Parthasarathy
Fowler, Benjamin J
Wright, Charles B
Apicella, Ivana
Greco, Adelaide
Brunetti, Arturo https://orcid.org/0000-0001-7057-3494
Ruvo, Menotti
Sandomenico, Annamaria
Nozaki, Miho
Ijima, Ryo
Kaneko, Hiroki https://orcid.org/0000-0003-0731-6465
Ogura, Yuichiro
Terasaki, Hiroko
Ambati, Balamurali K
Leusen, Jeanette HW
Langdon, Wallace Y
Clark, Michael R https://orcid.org/0000-0002-5539-4997
Armour, Kathryn L
Bruhns, Pierre
Verbeek, J Sjef
Gelfand, Bradley D
De Falco, Sandro
Ambati, Jayakrishna
- License Information
-
More Information
Article History
Received: 28 August 2015
Revised: 25 November 2015
Accepted: 25 November 2015
First Online: 28 January 2016
Competing interests
: JA is a co-founder of iVeena Holdings, iVeena Pharmaceuticals, iVeena Delivery Systems and Inflammasome Therapeutics, and has received honoraria from Allergan and research funding from Olix Pharmaceuticals unrelated to this work. JA and SDF are named as inventors on patent applications filed by the University of Kentucky relating to the technology described in this work. MRC is listed as an inventor on patents covering alemtuzumab and MRC and KLA are listed as inventors on patents covering the Fc mutated forms of alemtuzumab.
